MCID: CLT003
MIFTS: 60

Colitis malady

Categories: Gastrointestinal diseases

Aliases & Classifications for Colitis

Summaries for Colitis

Disease Ontology : 12 An inflammatory bowel disease that involves inflammation located in colon.

MalaCards based summary : Colitis is related to clostridium difficile colitis and crohn's colitis. An important gene associated with Colitis is TNF (Tumor Necrosis Factor), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Infliximab and Sucralfate have been mentioned in the context of this disorder. Affiliated tissues include colon, t cells and neutrophil, and related phenotypes are Increased shRNA abundance (Z-score > 2) and hematopoietic system

Wikipedia : 71 Colitis is an inflammation of the colon. Colitis may be acute and self-limited or long-term. It broadly... more...

Related Diseases for Colitis

Diseases related to Colitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 754)
id Related Disease Score Top Affiliating Genes
1 clostridium difficile colitis 33.8 IFNG IL2 IL6 TNF
2 crohn's colitis 33.4 IL17A IL6 MPO NOD2 TLR4 TNF
3 collagenous colitis 32.2 CXCL8 FOXP3 IFNG IL10 IL17A IL1B
4 pyoderma gangrenosum 32.1 CXCL8 IFNG IL1B IL6 TNF
5 colorectal cancer 31.8 CXCL8 IFNG IL10 IL1B IL2 IL6
6 hepatitis 30.5 IFNG IL10 IL2 IL6 TNF
7 pericholangitis 30.4 MPO MUC2 TLR4 TNF
8 celiac disease 30.3 IL17A NOD2 TNF
9 polyarteritis nodosa 30.0 IFNG IL17A TLR4
10 neuropathy 29.9 CXCL8 IL1B IL6 TLR4 TNF
11 tuberculosis 29.8 IL10 IL17A IL1B IL2 IL6 TNF
12 rosacea 29.8 IFNG IL10 IL1B
13 fasciitis 29.7 CXCL8 MPO TNF
14 pyelonephritis 29.7 CXCL8 IL10 IL1B NOS2 TNF
15 epidermolysis bullosa 29.6 IFNG IL17A NOD2 TNF
16 histiocytoma 29.5 CXCL8 NOD2 TNF
17 chronic lymphocytic leukemia 29.5 IFNG IL1B MPO TNF
18 cryptococcosis 29.5 IL10 IL17A TNF
19 labyrinthitis 29.4 CXCL8 IL10 IL1B IL6 TNF
20 colon adenocarcinoma 29.4 CXCL8 IL10 IL1B IL6 TNF
21 rheumatoid arthritis 29.4 CXCL8 FOXP3 IFNG IL10 IL17A IL1B
22 osteonecrosis 29.4 CXCL8 IL1B IL6 TNF
23 membranoproliferative glomerulonephritis 29.3 FOXP3 IL10 IL2 IL6 MUC2 TNF
24 histiocytosis 29.3 CXCL8 IL17A IL1B IL6 TLR4 TNF
25 ulcerative colitis 12.5
26 lymphocytic colitis 12.3
27 chemical colitis 12.3
28 microscopic colitis 12.2
29 diversion colitis 12.2
30 ischemic colitis 12.2
31 eosinophilic colitis 12.0
32 pediatric ulcerative colitis 11.9
33 undetermined colitis 11.9
34 cutaneous photosensitivity and colitis, lethal 11.8
35 leukoencephalopathy, arthritis, colitis, and hypogammaglobulinema 11.7
36 amebiasis 11.7
37 obesity-colitis-hypothyroidism-cardiac hypertrophy-developmental delay syndrome 11.7
38 epithelio-exfoliative colitis-deafness syndrome 11.7
39 crohn's disease 11.6
40 inflammatory bowel disease 1 11.4
41 gastroenteritis 11.3
42 ulcerative proctitis 11.2
43 pouchitis 11.2
44 inflammatory bowel disease 11.2
45 inflammatory bowel disease 25, early onset, autosomal recessive 11.1
46 hermansky-pudlak syndrome 11.0
47 bile duct carcinoma 11.0
48 collagenous gastritis 11.0
49 colonic disease 11.0
50 inflammatory bowel disease 14 10.8

Graphical network of the top 20 diseases related to Colitis:



Diseases related to Colitis

Symptoms & Phenotypes for Colitis

GenomeRNAi Phenotypes related to Colitis according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 10.39 MPO NOS2 IL1B UCN IL10
2 Increased shRNA abundance (Z-score > 2) GR00366-A-102 10.39 IL1B
3 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.39 NOS2 UCN
4 Increased shRNA abundance (Z-score > 2) GR00366-A-113 10.39 IL10
5 Increased shRNA abundance (Z-score > 2) GR00366-A-115 10.39 NOS2 UCN
6 Increased shRNA abundance (Z-score > 2) GR00366-A-123 10.39 NOS2
7 Increased shRNA abundance (Z-score > 2) GR00366-A-125 10.39 IL10
8 Increased shRNA abundance (Z-score > 2) GR00366-A-126 10.39 MPO
9 Increased shRNA abundance (Z-score > 2) GR00366-A-128 10.39 IL10
10 Increased shRNA abundance (Z-score > 2) GR00366-A-132 10.39 IL10
11 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.39 IL10
12 Increased shRNA abundance (Z-score > 2) GR00366-A-157 10.39 MPO
13 Increased shRNA abundance (Z-score > 2) GR00366-A-159 10.39 UCN
14 Increased shRNA abundance (Z-score > 2) GR00366-A-161 10.39 IL10
15 Increased shRNA abundance (Z-score > 2) GR00366-A-168 10.39 IL1B UCN
16 Increased shRNA abundance (Z-score > 2) GR00366-A-170 10.39 IL1B
17 Increased shRNA abundance (Z-score > 2) GR00366-A-176 10.39 MPO
18 Increased shRNA abundance (Z-score > 2) GR00366-A-186 10.39 MPO
19 Increased shRNA abundance (Z-score > 2) GR00366-A-197 10.39 NOS2
20 Increased shRNA abundance (Z-score > 2) GR00366-A-198 10.39 IL1B IL10
21 Increased shRNA abundance (Z-score > 2) GR00366-A-199 10.39 IL1B
22 Increased shRNA abundance (Z-score > 2) GR00366-A-210 10.39 IL10
23 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.39 IL10
24 Increased shRNA abundance (Z-score > 2) GR00366-A-25 10.39 IL10
25 Increased shRNA abundance (Z-score > 2) GR00366-A-29 10.39 MPO
26 Increased shRNA abundance (Z-score > 2) GR00366-A-36 10.39 MPO
27 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.39 UCN
28 Increased shRNA abundance (Z-score > 2) GR00366-A-47 10.39 NOS2
29 Increased shRNA abundance (Z-score > 2) GR00366-A-50 10.39 NOS2 IL1B
30 Increased shRNA abundance (Z-score > 2) GR00366-A-51 10.39 IL1B
31 Increased shRNA abundance (Z-score > 2) GR00366-A-52 10.39 IL10
32 Increased shRNA abundance (Z-score > 2) GR00366-A-57 10.39 MPO
33 Increased shRNA abundance (Z-score > 2) GR00366-A-67 10.39 IL10
34 Increased shRNA abundance (Z-score > 2) GR00366-A-7 10.39 MPO
35 Increased shRNA abundance (Z-score > 2) GR00366-A-70 10.39 MPO
36 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.39 UCN
37 Increased shRNA abundance (Z-score > 2) GR00366-A-79 10.39 IL1B
38 Increased shRNA abundance (Z-score > 2) GR00366-A-80 10.39 IL10
39 Increased shRNA abundance (Z-score > 2) GR00366-A-81 10.39 IL1B
40 Increased shRNA abundance (Z-score > 2) GR00366-A-82 10.39 IL10
41 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.39 NOS2 IL10
42 Increased shRNA abundance (Z-score > 2) GR00366-A-90 10.39 NOS2
43 Increased shRNA abundance (Z-score > 2) GR00366-A-99 10.39 NOS2 UCN
44 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.92 MPO MYO9B NOD2 NOS2 TNF CXCL8
45 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.92 MYO9B NOD2 NOS2 TNF CXCL8 IL10

MGI Mouse Phenotypes related to Colitis:

44 (show all 15)
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.35 FOXP3 IFNG IL10 IL17A IL1B IL2
2 cardiovascular system MP:0005385 10.33 FOXP3 IFNG IL10 IL1B IL2 IL6
3 homeostasis/metabolism MP:0005376 10.33 IL6 MPO MUC2 NOD2 NOS2 REL
4 cellular MP:0005384 10.31 IL2 IL6 MUC2 MYO9B NOD2 NOS2
5 immune system MP:0005387 10.31 TLR4 TNF FOXP3 IFNG IL10 IL17A
6 digestive/alimentary MP:0005381 10.3 TNF FOXP3 IFNG IL10 IL17A IL2
7 growth/size/body region MP:0005378 10.27 TNF FOXP3 IFNG IL10 IL17A IL2
8 mortality/aging MP:0010768 10.17 FOXP3 IFNG IL10 IL17A IL1B IL2
9 endocrine/exocrine gland MP:0005379 10.16 FOXP3 IFNG IL10 IL17A IL2 IL6
10 integument MP:0010771 10.06 FOXP3 IFNG IL10 IL1B IL6 NOS2
11 liver/biliary system MP:0005370 10.02 TLR4 TNF FOXP3 IFNG IL10 IL2
12 neoplasm MP:0002006 9.91 IL6 MUC2 NOS2 TLR4 TNF IFNG
13 respiratory system MP:0005388 9.85 FOXP3 IFNG IL10 IL17A IL2 IL6
14 skeleton MP:0005390 9.65 IFNG IL10 IL17A IL1B IL6 NOD2
15 vision/eye MP:0005391 9.23 NOS2 TLR4 TNF FOXP3 IFNG IL10

Drugs & Therapeutics for Colitis

Drugs for Colitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 377)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Infliximab Approved Phase 4,Phase 2,Phase 3,Phase 1 170277-31-3
2
Sucralfate Approved Phase 4 54182-58-0
3
Adalimumab Approved Phase 4,Phase 3,Phase 2,Phase 1 331731-18-1 16219006
4
Ciprofloxacin Approved, Investigational Phase 4,Phase 3,Phase 2 85721-33-1 2764
5
Azathioprine Approved Phase 4,Phase 2,Phase 3 446-86-6 2265
6
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 3 53-03-2 5865
7
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 2 564-25-0 54671203
8
Aminosalicylic Acid Approved Phase 4,Phase 3,Phase 2,Phase 1 65-49-6 4649
9
Omeprazole Approved, Investigational, Vet_approved Phase 4,Phase 1,Phase 2 73590-58-6 4594
10
Vancomycin Approved Phase 4,Phase 3,Phase 2,Phase 1 1404-90-6 441141 14969
11
Loperamide Approved Phase 4,Phase 3,Phase 2 53179-11-6 3955
12
Cyclosporine Approved, Investigational, Vet_approved Phase 4,Phase 2 79217-60-0, 59865-13-3 5284373 6435893
13
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2 22916-47-8 4189
14
Benzocaine Approved Phase 4,Phase 3,Phase 1 1994-09-7, 94-09-7 2337
15
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2 104987-11-3 445643 439492
16
Iron Approved Phase 4,Phase 3,Phase 2 7439-89-6 23925
17
Menthol Approved Phase 4,Phase 2 2216-51-5 16666
18
Rifaximin Approved, Investigational Phase 4 80621-81-4 6436173
19
Bupropion Approved Phase 4 34841-39-9, 34911-55-2 444
20
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
21
Cefazolin Approved Phase 4 25953-19-9 656510 33255
22
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
23
Amoxicillin Approved, Vet_approved Phase 4,Phase 3 26787-78-0 33613 2171
24
Metronidazole Approved Phase 4,Phase 3,Phase 2,Phase 1 443-48-1 4173
25
Nicotine Approved Phase 4 54-11-5 942 89594
26
Vedolizumab Approved Phase 4,Phase 3,Phase 2,Early Phase 1 943609-66-3
27
Hydrocortisone Approved, Vet_approved Phase 4,Phase 1,Phase 2 50-23-7 5754 657311
28
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
29
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
30
Guaifenesin Approved, Vet_approved Phase 4,Phase 3,Phase 1 93-14-1 3516
31
Sulfamethoxazole Approved Phase 4 723-46-6 5329
32
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
33
Methotrexate Approved Phase 4,Phase 2 1959-05-2, 59-05-2 126941
34
Dextromethorphan Approved Phase 4 125-71-3 5360696 5362449
35
Losartan Approved Phase 4 114798-26-4 3961
36
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
37
Ursodeoxycholic acid Approved, Investigational Phase 4 128-13-2 31401
38
Copper Approved Phase 4 15158-11-9, 7440-50-8 27099
39
Zinc Approved Phase 4 7440-66-6 32051 23994
40
Thioguanine Approved Phase 4 154-42-7 2723601
41
Cephalexin Approved, Vet_approved Phase 4 15686-71-2 27447
42
Nitrofurantoin Approved, Vet_approved Phase 4 67-20-9 5353830
43
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
44 tannic acid Approved, Nutraceutical Phase 4,Phase 3,Phase 1
45
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 1 59-30-3 6037
46
leucovorin Approved, Nutraceutical Phase 4,Phase 2 58-05-9 54575, 6560146 143
47
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 5785 54670067
48
Cholecalciferol Approved, Nutraceutical Phase 4,Phase 3,Phase 1,Phase 2 67-97-0 6221 10883523 5280795
49
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 3,Phase 1,Phase 2 50-14-6 5280793
50
Caffeine Approved, Nutraceutical Phase 4 58-08-2 2519

Interventional clinical trials:

(show top 50) (show all 992)
id Name Status NCT ID Phase
1 Role of Healthy Bacteria in Ulcerative Colitis Unknown status NCT01479660 Phase 4
2 Golimumab in Steroid-dependent Ulcerative Colitis: Induction and Maintenance of Clinical and Endoscopic Remission Unknown status NCT02412085 Phase 4
3 Physiological Intermolecular Modification Spectroscopy (PIMS) in Ulcerative Colitis With Golimumab Unknown status NCT02186886 Phase 4
4 Clostridial Infection and Oral Lavage -Improving Treatment Before Illness Becomes Severe Unknown status NCT01630096 Phase 4
5 "Efficacy and Safety of Infliximab-biosimilar (Inflectra) Compared to Infliximab-innovator (Remicade) in Patients With Inflammatory Bowel Disease in Remission: the SIMILAR Trial" Unknown status NCT02452151 Phase 4
6 The Effect of Probiotics on the Rate of Recovery of Inflammatory Bowel Disease Exacerbation, Endothelial Function, and Markers of Inflammation Unknown status NCT01078935 Phase 4
7 Confocal Endomicroscopy During Endoscopy Unknown status NCT00988273 Phase 4
8 A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Unknown status NCT01632462 Phase 4
9 The Effect of Probiotics on Exacerbation of Inflammatory Bowel Disease Exacerbation (Crohn's Disease) Unknown status NCT01765998 Phase 4
10 Manipulation of Visceral Sensitivity and Immune System in IBS Unknown status NCT00418340 Phase 4
11 ZeroTolerance Mucositis: Managing Oral and Alimentary Mucositis With High Potency Sucralfate - ProThelial Unknown status NCT02016807 Phase 4
12 Use of Combined Measurements of Serum Infliximab and Anti-infliximab Antibodies in the Treatment of Patients With Crohns Disease Failing Infliximab Therapy Unknown status NCT00851565 Phase 4
13 Golimumab Utilization and Impact on Ulcerative Colitis (MK-8259-032) Completed NCT02092285 Phase 4
14 Treatment of Ulcerative Colitis With Ciprofloxacin and E. Coli Nissle Completed NCT01772615 Phase 4
15 A Long Term Safety Study of Infliximab (Remicade) in in Ulcerative Colitis Patients Completed NCT00207688 Phase 4
16 Evaluation of Histologic and Endoscopic Remission Induced by Infliximab in Moderate to Severe Ulcerative Colitis Completed NCT01408810 Phase 4
17 Strategies in Maintenance for Patients Receiving Long-term Therapy (S.I.M.P.L.E.) With MMX (Multi-Matrix System) Mesalamine for Ulcerative Colitis (UC) Completed NCT00446849 Phase 4
18 Study Comparing Cyclosporine With Infliximab in Steroid-refractory Severe Attacks of Ulcerative Colitis Completed NCT00542152 Phase 4
19 European Safety Registry in Ulcerative Colitis (Study P04808AM3) Completed NCT00705484 Phase 4
20 Once Versus Twice Daily Mesalamine to Induce Remission in Pediatric Ulcerative Colitis Completed NCT01201122 Phase 4
21 Asacol Dosing Study for Active Ulcerative Colitis Completed NCT00194818 Phase 4
22 Preference for a Prefilled Syringe or Smartject™ Device for Delivering Golimumab in Participants Suffering From Moderate-to-severe Ulcerative Colitis (MK-8259-027) Completed NCT02155335 Phase 4
23 Adacolumn in Refractory UC Patients Trial Completed NCT01481142 Phase 4
24 Dose Escalation and Remission (DEAR) Completed NCT00652145 Phase 4
25 Ability to Maintain or Achieve Clinical and Endoscopic Remission With MMX Mesalamine Once Daily in Adults With Ulcerative Colitis Completed NCT01124149 Phase 4
26 Study for the Treatment of Ulcerative Colitis With Adacolumn (Companion to US Study 512-04-205) Completed NCT00219414 Phase 4
27 Association Between Response to Treatment of C. Diff Colitis and Anti-C.Diff Toxin Antibody Completed NCT00304408 Phase 4
28 Rectal Tacrolimus in the Treatment of Resistant Ulcerative Proctitis Completed NCT01418131 Phase 4
29 Safety of Accelerated Infliximab Infusions in Patients With Inflammatory Bowel Disease (IBD) Completed NCT01346826 Phase 4
30 Treatment of Iron Deficiency Anaemia in Inflammatory Bowel Disease With Ferrous Sulphate Completed NCT01991314 Phase 4
31 Low Volume Colon Preparation for IBD Completed NCT02248337 Phase 4
32 Induction of Immunity Against Streptococcus Pneumoniae in Adults With Inflammatory Bowel Disease Completed NCT01908283 Phase 4
33 Impact of Six Patient Information Leaflets (PIL) on Doctor Patient Communication Completed NCT02246361 Phase 4
34 Single-dose Linaclotide for Capsule Endoscopy Preparation Completed NCT02465385 Phase 4
35 The Influence of 5–Aminosalicylates on Thiopurine Metabolite Levels Completed NCT00167882 Phase 4
36 Immunogenicity of Hepatitis A Vaccine in Inflammatory Bowel Disease (IBD) Patients Completed NCT01341808 Phase 4
37 Steroid-induced Mood Changes in Patients With Inflammatory Bowel Disease Completed NCT01981889 Phase 4
38 Rifaximin for Preventing Relapse of Clostridium Associated Diarrhoea Completed NCT01670149 Phase 4
39 Efficacy Study of Pneumococcal Vaccination in Crohn's Disease Completed NCT01505855 Phase 4
40 Intestinal Inflammation in Ankylosing Spondylitis and the Effects of Adalimumab on Mucosal Healing Completed NCT01174186 Phase 4
41 Immune Response to the Human Papillomavirus Vaccine in Young Women With Inflammatory Bowel Disease Completed NCT01034358 Phase 4
42 A Trial of Iron Replacement in Patients With Iron Deficiency. Completed NCT01067547 Phase 4
43 Treating Disrupted Sleep in Individuals With Inflammatory Bowel Disease Completed NCT02162862 Phase 4
44 Postoperative Antibiotic Requirements Following Immediate Breast Reconstruction Completed NCT01244698 Phase 4
45 Use of a Novel Diet (UC DIET) for Treatment of Mild to Moderate Active Pediatric Ulcerative Colitis Recruiting NCT02345733 Phase 4
46 Optimising Infliximab Induction Therapy for Acute Severe Ulcerative Colitis Recruiting NCT02770040 Phase 4
47 Golimumab (GLM) Dose Optimisation to Adequate Levels to Achieve Response in Colitis Recruiting NCT02687724 Phase 4
48 Vedolizumab Intravenous (IV) Dose Optimization in Ulcerative Colitis Recruiting NCT03029143 Phase 4
49 Two Therapeutic Strategies for the Maintenance of Remission in Patients With Ulcerative Colitis Recruiting NCT03151525 Phase 4
50 Corticosteroids+5-aminosalicylic Acid Compared to Corticosteroids in the Treatment of Moderate-severe Ulcerative Colitis Recruiting NCT01941589 Phase 4

Search NIH Clinical Center for Colitis

Cochrane evidence based reviews: colitis

Genetic Tests for Colitis

Genetic tests related to Colitis:

id Genetic test Affiliating Genes
1 Colitis 29

Anatomical Context for Colitis

MalaCards organs/tissues related to Colitis:

39
Colon, T Cells, Neutrophil, Liver, Monocytes, Bone, Endothelial

The Foundational Model of Anatomy Ontology organs/tissues related to Colitis:

18
Colon

Publications for Colitis

Articles related to Colitis:

(show top 50) (show all 4337)
id Title Authors Year
1
Traditional Chinese medicine combination therapy for patients with steroid-dependent ulcerative colitis: study protocol for a randomized controlled trial. ( 28069051 )
2017
2
Continuing Medical Education Questions: January 2017: Diagnosis and Management of Microscopic Colitis. ( 28050038 )
2017
3
Squamous cell dysplasia in the proximal rectum of three patients treated for ulcerative colitis on immunomodulators. ( 28091842 )
2017
4
Primary Colonic Eosinophilia and Eosinophilic Colitis in Adults. ( 27792062 )
2017
5
Mucosal Healing in Ulcerative Colitis: A Comprehensive Review. ( 28078646 )
2017
6
Effect of threatening life experiences and adverse family relations in ulcerative colitis: analysis using structural equation modeling and comparison with Crohn's disease. ( 28059861 )
2017
7
Efficacy and Safety of Vedolizumab in Ulcerative Colitis and Crohn's Disease Patients Stratified by Age. ( 28070861 )
2017
8
Sijunzi Decoction attenuates 2, 4, 6-trinitrobenzene sulfonic acid (TNBS)-induced colitis in rats and ameliorates TNBS-induced claudin-2 damage via NF-I_B pathway in Caco2 cells. ( 28073341 )
2017
9
Review article: dose optimisation of infliximab for acute severe ulcerative colitis. ( 28074618 )
2017
10
Etiopathogenesis of Nephrolithiasis in Ulcerative Colitis Patients with the Ileal Pouch Anal Anastomosis. ( 28301430 )
2017
11
Prevention of colitis-associated cancer by selective targeting of immunoproteasome subunit LMP7. ( 28086242 )
2017
12
Granulocyte-Monocyte Apheresis as an Adjuvant Therapy to Anti-Tumor Necrosis Factor Drugs for Ulcerative Colitis. ( 28078747 )
2017
13
Functional variant in the promoter region of IL-27 alters gene transcription and confers a risk for ulcerative colitis in northern Chinese Han. ( 28069403 )
2017
14
Interaction of Ethnicity and H. pylori Infection in the Occurrence of Microscopic Colitis. ( 28070826 )
2017
15
Gastrointestinal diseases and their oro-dental manifestations: Part 2: Ulcerative colitis. ( 28084352 )
2017
16
Surveillance for Dysplasia in Patients with Ulcerative Colitis: Discrepancy between Guidelines and Practice. ( 28066941 )
2017
17
Proteinase 3-antineutrophil cytoplasmic antibody-positive ulcerative colitis presenting with abducens neuropathy. ( 28069788 )
2017
18
Continuing Medical Education: January 2017: Diagnosis and Management of Microscopic Colitis. ( 28050030 )
2017
19
Diagnosis and Management of Microscopic Colitis. ( 27897155 )
2017
20
Microscopic colitis: a missed diagnosis among patients with moderate to severe irritable bowel syndrome. ( 27796144 )
2017
21
Fulminant gangrenous ischemic colitis: is it the solely severe type of ischemic colitis? ( 27838817 )
2017
22
Manipulation of the Endocannabinoid System in Colitis: A Comprehensive Review. ( 28079617 )
2017
23
Unsuspected Active Ulcerative Colitis in a Patient With Dermatomyositis: A Rare Association Detected on (18)F-FDG PET/CT During the Search for an Occult Malignancy. ( 28533643 )
2017
24
Inhibition of Matrix Metalloproteinase-9 by a Barbiturate-Nitrate Hybrid Ameliorates Dextran Sulphate Sodium-Induced Colitis: Effect on Inflammation-Related Genes. ( 28079248 )
2017
25
Tripeptide K(D)PT Is Well Tolerated in Mild-to-moderate Ulcerative Colitis: Results from a Randomized Multicenter Study. ( 28092306 )
2017
26
Neutrophil-to-Lymphocyte Ratio for Predicting Loss of Response to Infliximab in Ulcerative Colitis. ( 28076386 )
2017
27
The Ileitis of Ulcerative Colitis. Why Is It Not Crohn's Disease? ( 28079623 )
2017
28
Exacerbation caused by 5-ASA intolerance in children with ulcerative colitis. ( 28063246 )
2017
29
Long-term Extent Change of Pediatric-Onset Ulcerative Colitis. ( 28067753 )
2017
30
Activation of NLRP3 Inflammasome in Inflammatory Bowel Disease: Differences Between Crohn's Disease and Ulcerative Colitis. ( 28523573 )
2017
31
Insights into the pathophysiology of ulcerative colitis: interleukin-13 modulates STAT6 and p38 MAPK activity in the colon epithelial sodium channel. ( 28083943 )
2017
32
Immune-protective effect of echinococcosis on colitis experimental model is dependent of down regulation of TNF-I+ and NO production. ( 27983971 )
2017
33
Crohn's Disease and Ulcerative Colitis Show Unique Cytokine Profiles. ( 28533995 )
2017
34
Pouchitis after ileal pouch-anal anastomosis in ulcerative colitis: Diagnosis, management, risk factors, and incidence. ( 27681447 )
2017
35
Involvement of Activated Cdc42 Kinase1 in Colitis and Colorectal Neoplasms. ( 27926694 )
2016
36
Corticotropin-Releasing Hormone Receptor 2 Signaling Promotes Mucosal Repair Responses after Colitis. ( 26597886 )
2016
37
Diagnosis and treatment of microscopic colitis. ( 27271790 )
2016
38
An Unusual Case of Intestinal Obstruction in Ulcerative Colitis. ( 27810371 )
2016
39
Beyond Low Flow: How I Manage Ischemic Colitis. ( 27725651 )
2016
40
Spinal epidural abscess: a rare complication of ulcerative colitis after ileal pouch anal anastomosis. ( 27822874 )
2016
41
Update on ischemic colitis: from etiopathology to treatment including patients of intensive care unit. ( 27152750 )
2016
42
FNDC4 acts as an anti-inflammatory factor on macrophages and improves colitis in mice. ( 27066907 )
2016
43
A galectin-specific signature in the gut delineates Crohn's disease and ulcerative colitis from other human inflammatory intestinal disorders. ( 26891020 )
2016
44
Ulcerative Colitis in Colonic Interposition for Esophageal Atresia. ( 27847835 )
2016
45
Colorectal cancer in Crohn's colitis is comparable to sporadic colorectal cancer. ( 27026089 )
2016
46
Colitis as the Sole Initial Presentation of Chronic Granulomatous Disease: Histopathologic Clues to Diagnosis. ( 27331854 )
2016
47
Prevalence and Natural History of Microscopic Colitis: A Population-Based Study With Long-term Clinical Follow-up in Terrassa, Spain. ( 26818762 )
2016
48
Herpes simplex induced necrotizing tonsillitis in an immunocompromised patient with ulcerative colitis. ( 26881193 )
2016
49
Ischemic Colitis after Cardiac Surgery: Can We Foresee the Threat? ( 27977704 )
2016
50
Challenges in detection and real-time diagnosis of dysplasia in Crohn's colitis: the search still continues. ( 27102530 )
2016